Ireland
--:--IST
Latest
Clinical Trials in Portugal / NCT06882850
Recruiting Observational

Immunomodulation During Pregnancy

NCT06882850 · tracked via the Priya Life Science Portugal tracker
Phase
Observational
Started
2024-02-01
Last updated
2025-03-19

Condition(s) studied

AspirinPregnancy ComplicationsImmunology

Study summary

The goal of this observational study is to learn about the effects of low dose aspirin in immunity Pregnant women taking aspirin for other reasons (preeclampsia prevention) will be studied. The main question it aims to answer is: evaluate the effect of LDA on the modulation of innate immunity cells (NK cells, monocytes, γδ T cells) and/or acquired immunity (B and T lymphocytes, Treg cells, Th cells).

Participants already taking intervention A as part of their regular medical care for RA will answer online survey questions about their joint pain for 5 years.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: - Singleton pregnancy * Patients attending prenatal consultations at the Obstetrics Service A of CHUC, with the first consultation occurring before 14 weeks of gestation * Gestational age determined by first-trimester ultrasound * Study group: Women classified as high risk for PE according to clinical/historical criteria and the Fetal Medicine Foundation algorithm. LDA-naïve. Exclusion Criteria: Multiple pregnancy * Autoimmune diseases * Prior use of LDA or other immunomodulatory medication before potential recruitment * History of spontaneous miscarriages and/or medical termination of pregnancy * Fetal malformation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Unidade Local de Saúde de Coimbra, E.P.E. Coimbra Coimbra District Recruiting

More Unidade Local de Saúde de Coimbra, EPE trials in Portugal

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06882850 on ClinicalTrials.gov ↗ ← All trials in Portugal